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Abstract 
Background : Individuals with Parkinson's disease (PD) often present visual symptoms (eg. 
difficulty in reading, double vision) that can also be found in convergence insufficiency (CI). 
The objective was to estimate the prevalence of CI-type visual symptomatology in individuals 
with PD, in comparison with controls. 
 
Methods : Participants ≥ 50 yrs with (n= 300) and without (n= 300) PD were recruited. They 
were administered the Convergence Insufficiency Symptom Survey (CISS-15) over the phone. A 
score of ≥ 21 on the CISS-15, considered positive for CI-type symptomatology, served as cut-
off. Data from individuals (n= 87 with, n= 94 without PD) who were approached but who 
reported having a known oculovisual condition were analyzed separately. Student t test and Chi-
square at the 0.05 level were used for statistical significance. 
 
Results : 29.3% of participants with vs 7.3% without PD presented a score of ≥ 21 on the CISS-
15 (p= 0.001). Of the participants having a known oculovisual condition, 39.1% with vs 19.1% 
without PD presented a score of ≥ 21 on the CISS-15 (p= 0.01).   
 
Conclusion : The prevalence of CI-type visual symptoms is higher in individuals with vs without 
PD whether or not they have a co-existing oculovisual condition. These results suggest that PD 
per se places individuals with the disease at greater risk of visual symptomatology. These results 
further underline the importance of providing regular eye exams to individuals with PD. 
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Introduction : 
Patients with Parkinson's disease (PD) have a variety of non-motor symptoms that are becoming 
more recognized1. Among these are oculovisual symptoms such as dry eyes2, difficulty reading 
and double vision1,3 that can affect quality of life in PD patients. Alterations in some visual 
functions have also been documented in PD, among which is convergence insufficiency (CI), a 
decreased ability to converge both eyes on an object located at near distance2.  When present, CI 
can lead to blurred vision, tearing, ocular fatigue, double vision and make it difficult or 
impossible for a person to read comfortably. This can be detrimental to many aspects of a 
person's life in modern countries where the ability to read efficiently permeates the educational, 
working or even recreational environments. 
 
Over the last two decades, a few studies have addressed CI-type symptomatology in individuals 
with PD2-6. The CI-related symptoms most frequently cited in PD were difficulty reading and 
diplopia. All of these studies, however, were conducted on limited numbers of participants and 
none used a questionnaire developed and validated for CI. Our objective was to estimate the 
prevalence of CI-type symptomatology in a systematic fashion, in a large population of 
individuals with PD, compared to age-matched controls.  
 
Methods : 
This study was conducted in collaboration with the Institut universitaire de gériatrie de Montréal 
(IUGM), the Centre hospitalier de l'Université de Montréal (CHUM) and the Montreal General 
Hospital (MGH). The study protocol was approved by the Research Ethics Committee of each of 
the three hospitals and the study was conducted according to the Declaration of Helsinki. 
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Participants signed an informed consent in accordance with the requirements of the various 
ethics committees.	 
 
A total of 300 participants ≥ 50 yrs of age with a clinical diagnosis of PD were recruited from the 
Movement Disorder Clinics (MDC) of the neurology department at the CHUM and MGH 
(Figure 1). They were each matched for age (± 5 yrs) and opposite sex to a control participant 
without PD. Opposite sex was used in trying to facilitate recruitment in case spouses would be 
interested in participating and knowing that a gender-related prevalence of CI has not been 
documented7. A control was chosen among the spouse, family or friends of each participant with 
PD and if none was found, then the control was recruited from the bank of participants at the 
IUGM. A few controls had to be recruited from a third alternative source, i.e. the Clinique 
universitaire de la vision de l'Université de Montréal. The matching was done with a spouse 
(20.0%), a family member (0.3%) or another unrelated adult (79.7%). 
 
A review of clinical charts excluded individuals where binocular dysfunction other than CI (eg. 
strabismus), known ocular disease/decreased visual acuity (eg. glaucoma, age-related macular 
degeneration, amblyopia), other forms of neurodegenerative disease (eg. Huntington’s disease, 
dementia) or diseases likely to affect the extraocular muscles (eg. Graves’ thyroid disease, 
myasthenia gravis) or visual function (eg. diabetes) were reported.  
 
Individuals who met the study criteria based on their clinical chart review were contacted by 
mail and provided the following documents: research neurologist’s letter explaining the study, 
ethics documents including the information and consent, answer codes for the convergence 
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insufficiency symptom survey (CISS-15) questionnaire. Approximately 10 days later the 
research assistant (RA) called each individual to answer any questions and determine if they 
were interested in taking part in the study. If individuals did not want to participate no other 
contact was made. If a person was interested in participating, he/she was first allowed to ask any 
question related to the study, and was then given the choice to answer the phone questionnaires 
right away or at any other convenient time. The participant was asked to sign the consent form 
and mail it to the research team, according to each Ethic committee's requirement.   
 
Phone interviews lasted about 30 minutes on average. Four questionnaires were filled over the 
phone by the RA, in the following order: 1) Adult Lifestyles Function Interview (ALFI), 2) 
Ocular history, 3) General health, and 4) CISS-15. The first three questionnaires were used to 
further assess the eligibility of study participants. The ALFI is a telephone-administered version 
of the Mini-Mental State Examination (MMSE), that comprises 22 items aimed at screening for 
cognitive impairment8. A score below 14 was used as an exclusion criterion9. The ocular history 
and general health questionnaires were developed by the clinician/researcher specialists on our 
team, to ensure that the conditions specified by our inclusion/exclusion criteria were met. The 
CISS-15 questionnaire10 was designed to estimate the frequency and severity of CI symptoms 
and has been shown to be a valid and reliable instrument for CI treatment outcomes11. It contains 
15 items with a 5 digit scale from 0 to 4. The response to each item expresses the frequency of 
symptom occurrence (0= never; 4= always) and the potential total score, obtained by adding the 
individual response scores, ranges from 0 to 60, higher scores indicating greater symptom 
severity. A score of 21 has been shown to distinguish between symptomatic (≥ 21) vs 
asymptomatic (< 21) individuals11 and served as the cut-off for CI-type symptomatology in this 
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study. All individuals who consented to participate were asked to answer the 4 questionnaires 
over the phone. Some had to be excluded from the main study because they indicated having a 
binocular dysfunction other than CI or an ocular disease. Their data were kept and entered in a 
different Excel spreadsheet.  
 
The statistical average differences and percentage differences between two independent groups 
were respectively determined using the Student t test and Chi-square at the 0.05 level of 
significance. 
 
Results : 
 
The PD group included 121 women and 179 men with an average age of 67.3 ± 8.9 yrs, while the 
control group comprised 179 women and 121 men with an average age of 67.2 ± 8.7 yrs (p> 
0.05). The participants with PD had an average of 2.9 ± 1.7 diseases, were taking 5.1 ± 2.8 
medications, including 2.3 ± 1.1 PD-related medications, while the controls had an average of 
1.6 ± 1.4 diseases and were taking 2.1 ± 2.2 medications (p< 0.001). The mean duration of PD 
was 8.4 ± 5.9 yrs. The group-average score on the ALFI was 19.5 ± 2.3 for PD participants and 
20.3 ± 1.9 for controls (p= 0.001). The group-average score on the CISS-15 was 15.7 ± 9.3 for 
PD participants and 10.3 ± 7.0 for controls (p= 0.001). 29.3% (n= 88) of PD participants and 
7.3% (n= 22) of controls (p= 0.001) had scores on the CISS-15 of ≥ 21.  
 
87 participants with (36 women) and 94 without (68 women) PD were excluded from the main 
study for known ocular disease (n= 51 PD; n= 57 controls) or binocular vision anomaly other 
than CI (n= 36 PD; n= 37 controls). (Figure 2) Their average age was 70.5 ± 9.7 yrs for the PD 
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participants and 70.7 ± 8.9 yrs for the controls (p> 0.05). The participants with PD had an 
average of 3.8 ± 2.0 diseases, were taking 5.9 ± 2.6 medications, including 2.3 ± 1.1 PD-related 
medications, while the controls had an average of 2.0 ± 1.9 diseases and were taking 2.5 ± 2.0 
medications (p< 0.01).  The mean duration of PD was 9.0 ± 6.3 yrs. The group-average score on 
the ALFI was 18.9 ± 2.4 for PD participants and 20.1 ± 1.8 for controls (p= 0.001). The group-
average score on the CISS-15 was 19.3 ± 11.2 for PD participants and 13.7 ± 9.2 for controls (p= 
0.001). A score on the CISS-15 of ≥ 21 was obtained for 39.1% (n= 34) participants with and 
19.1% (n= 18) without PD (p= 0.01).   
 
An analysis of individual CISS symptoms in participants having positive CI symptomatology, 
revealed that "eyes feel tired" and "eyes feel uncomfortable" when reading or doing close work 
stood out the most for PD and non-PD participants. (Table 1) Those that emerged least were 
"headache" for "included/excluded" PD / "included" non-PD participants, and "double vision" 
for "excluded" non-PD participants. 
 
Discussion : 
This study indicates that CI-type visual symptomatology: 1) is higher in PD vs non-PD 
participants, 2) remains higher in PD vs non-PD participants, for those having a known 
oculovisual condition, and 3) is higher in PD and non-PD participants having vs not having a 
known oculovisual condition. Overall, these results indicate that having a known oculovisual 
condition is accompanied by a high prevalence of visual symptoms and they further suggest that 
having PD per se places individuals with the disease at higher risk of visual symptomatology.  
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The prevalence of CI-type visual symptomatology in individuals with PD (29.3%) was found to 
be 4 times greater than for those without PD (7.3%), and 2 times higher in PD (39.1%) vs non-
PD (19.1%) for individuals with a pre-existing oculovisual condition. These results are rather 
strong and deserve some interpretation. It is important to point out that the CISS-15 
questionnaire used in the present study was originally designed by experts to address the 
symptoms most likely to be present in individuals having a diagnosis of CI, to serve as an 
outcome measure of success for CI treatment. In other words, this questionnaire was to be used 
in people already having a diagnosis of CI, and was not meant to serve as a screening tool for CI. 
Knowing this limitation, the CISS-15 questionnaire was used here since it was the only existing 
validated tool to at least enquire about "CI-type" symptoms that could be used in a large number 
of participants. The similarity of symptoms found in CI and in other oculovisual conditions could 
have increased the prevalence of symptoms found in the present study. The elevation of CISS 
scores in those having a known oculovisual condition is consistent with this. The present results 
confirm those obtained in our previous report12, indicating that "eyes feel tired or uncomfortable 
while reading or doing close work" is a more prevalent/severe symptom than "double vision" in 
that population and suggest that this item could be added in non-motor screens to better identify 
PD individuals with vision problems. It is important also to point out that our data showing a 
higher prevalence of CI-type symptomatology in PD does not indicate that a diagnosis of CI is 
more prevalent in PD. Further research that would include a complete eye exam is needed to 
address this issue and has been pursued in view of the strength of the results obtained here. 
Although the limited resources available for the present study prevented the provision of an eye 
exam for all participants, we have been able to perform eye exams in a subset of 80 PD and 80 
non-PD participants. Results from this research have shown that a clinical diagnosis of CI is in 
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fact more prevalent in PD (43.8%) vs non-PD (16.3%) participants12. Taken together, these 
prevalence data underline the importance of evaluating oculovisual symptomatology and CI in 
individuals with PD. Oculovisual symptomatology being particularly prevalent in PD, it is 
important to provide these individuals with regular eye exams and treat any underlying 
oculovisual condition if at all possible. If symptoms were to be linked with a diagnosis of CI, in 
patients experiencing significant discomfort and decreased quality of life, then it could be 
possible to offer them some form of treatment such as prism or orthoptic therapy. These 
therapies would have to be decided upon based on the stability of the clinical findings however 
and, if judged of potential benefit, would have to be well explained and reserved to highly 
motivated patients, since they are known to work for older individuals13-15 but have not been 
formally evaluated in PD.  
 
Another limitation to this study is that we could not stage the severity of PD since the UPDRS 
ratings or Hoehn and Yahr staging were not available. Although this does not allow a 
comparison between severity of PD vs severity of CI-type symptomatology, it does not change 
the results that indicate a higher prevalence of CI-type symptomatology in PD vs non-PD 
individuals. In addition, using clinical charts to identify and recruit PD participants may have 
affected the population representativity of our sample but it would be difficult to give an opinion 
on the direction or magnitude of any potential selection bias. However, the strength of the data 
suggests that similar results would likely have been obtained in another PD population recruited 
under a different mode of selection. 
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Despite acknowledged limitations, the higher prevalence of symptoms found in those having PD 
certainly stresses the impact the disease has on the oculovisual system. It has been reported that 
ocular changes take place early on in the course of PD, likely a result of the disease itself2. Our 
results further suggest that particular care should be provided to patients with PD during an eye 
exam, to verify the extent of their symptoms and address them if at all possible. Similarly, as 
mentioned by Chaudhuri et al1, neurologists should also pay special attention to non-motor 
symptoms, including the oculovisual ones, in the care of their PD patients. This is particularly 
important knowing that PD medications can have a positive effect on visual function6,16. To that 
effect, it is worth mentioning that day-time somnolence has been linked with diplopia3. The 
authors suggested that drowsiness may alter the ability to maintain fusion3, a condition that may 
or may not be helped by PD medications, depending on whether the drowsiness is induced by a 
symptomatic undiagnosed binocular vision problem, by the medication itself, or due directly to 
the disease process itself (i.e. degeneration of wake-promoting nuclei). It is interesting to add 
that the issue of how ocular pathology contributes to disability in PD has been raised in a review 
paper addressing the retina in PD17. Although our results cannot provide any answer to that 
question, they certainly demonstrate that symptoms are higher in the presence of an ocular 
pathology or a visual dysfunction and they reinforce the importance of pursuing research aimed 
at better understanding vision in PD.  
 
In conclusion, our data have shown that CI-type symptomatology is higher in individuals with 
PD having or not a concurrent visual dysfunction or ocular pathology. Our results further stress 
the importance of providing regular eye exams for individuals affected by the disease. 
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